Treatment of mantle-cell lymphomas with the VAD +/- chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation

Annals of Oncology

Volumn 8, Issue SUPPL. 1, 1997, Pages

  Gressin, R ^a   Legouffe, E ^b   Leroux, D ^a   Jacob, M C ^a   Swiercz, P ^a   Peoch, M ^a   Capdevilla, V ^b   Rossi, J F ^b   Athyss, ^c   Sotto, J J ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

mantle cell lymphoma; non Hodgkin's lymphoma; VAD regimen

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; MELPHALAN;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION;

EID: 8244241091     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_1.S103     Document Type: Conference Paper

References (22)

1. Leroux D, Le Marc'Hadour F, Gressin R et al. Non-Hodgkin's lymphomas with t(11;14)(q13;q32): A subset of mantle zone/intermediate lymphocytic lymphoma? Br J Haematol 1994; 77: 346-53.
2. Banks PM, Chan J, Cleary ML et al. Mantle cell lymphoma: A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992; 16: 637-40.
3. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasm: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
4. Zucca E, Stein H, Coiffier B. On behalf of the European Lymphoma Task Force. European Lymphoma Task Force (ELTF): Report of the workshop on mantle cell lymphoma (MCL). Ann Oncol 1994; 5: 507-11.
5. Lennert K, Stein H, Kaiserling E. Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer 1975; 31 (Suppl 2): 29-43.
6. Berard CW, Dorfman RF. Histopathology of malignant lymphomas. Clin Haematol 1974; 3: 39-76.
7. Weisenburger DD, Kim H, Rappaport H. Mantle-zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma. Cancer 1982; 49: 1429-38.
8. Berger F, Felman P, Sonet A et al. Nonfollicular small B-cell lymphomas: A heterogeneous group of patients with distinct clinical features and outcome. Blood 1994; 83: 2829-35.
9. Zucca E, Roggero E, Pinotti G et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257-62.
10. Meusers P, Engelhard M, Bartels H et al. Multicenter randomized therapeutic trial for advanced centrocytic lymphoma: Anthracyclines does not improve the prognosis. Hematol Oncol 1989; 7: 365-80.
11. Norton AJ, Matthews J, Pappa V et al. Mantle cell lymphoma: Natural history defined in a serially biopsied population over 20-year period. Ann Oncol 1995; 6: 249-56.
12. Shivdasani RA, Hess JL, Skaring AT et al. Intermediate lymphocytic lymphoma: Clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 802-11.
13. Gressin R, Hubert C, Jacob MC et al. Centrocytic lymphomas. Blood 1994; 84 (Suppl 1):642A (Abstr 2553).
14. Pegourie-Bandelier B, Sotto JJ, Hollard D et al. Therapy program for patients with advanced stages of chronic lymphocytic leukemia: Chlorambucil, splenectomy, and total node irradiation. Cancer 1995; 75: 2853-61.
15. Medeiros LJ, Van Krieken JH, Jaffe ES et al. Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood 1990; 76: 2086-90.
16. Rosenberg CL, Wong E, Petty EM et al. PRADI, a candidate BCL1 oncogene: Mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 1991; 88: 9638-42.
17. Motokura T, Bloom T, Kim HG et al. A novel cyclin encoded by a bcl-1-linked candidate oncogene. Nature 1991; 350: 512-4.
18. Van den Berghe H. Chromosome in plasma-cell malignancies. Eur J Haematol 1989; 43 (Suppl 51): 47-51.
19. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86-90.
20. Stewart DA, Vose JM, Weisenburger DD et al. The role of high dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995; 6: 263-6.
21. Vose VM, Weisenburger DD, Anderson JR et al. Mantle cell lymphoma (MCL) has a poorer prognosis than follicular non Hodgkin's lymphoma; however, high dose therapy and autologous stem cell transplantation may overcome treatment resistance in MCL. Blood 1993; 82 (Suppl 1): 135A (Abstr 527).
22. Monteil M, Callanan M, Dascalescu C et al. Molecular diagnosis of t(11;14) in mantle cell lymphoma using two colour interphase fluorescent in situ hybridisation. Br J Haematol 1996; 93: 656-60.